Astellas and PeptiDream Forge $808M Collaboration to Develop Next-Generation Protein Degraders

On July 25, it was announced that a research collaboration and licensing agreement had been reached with Astellas to discover novel protein degraders targeting two selected Astellas targets. Additionally, Astellas has the option to include three more targets within the scope of the collaboration.

The two companies plan to combine PeptiDream's PDPS (Peptide Discovery Platform System) technology with Astellas' drug discovery capabilities to identify next-generation protein degraders against multiple different targets. Astellas will be responsible for the development and commercialization of the products generated from the collaboration.

Source: PeptiDream Inc. official website

Under the agreement, Astellas will pay PeptiDream Inc. an upfront payment of 3 billion yen. PeptiDream is also eligible to receive up to 20.6 billion yen in discovery, development, and commercial sales milestone payments for each of the five targets. Including the 3 billion yen upfront payment, the total transaction value could reach 106 billion yen (808 million USD).

In June this year, Astellas reached a research collaboration and exclusive option agreement with Cullgen to develop multiple innovative protein degraders, with a total value exceeding 1.9 billion US dollars.

PharmaCube Pro

New Targets, New Technologies, New Therapies

Media cooperation: 15895423126

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position; for republication, please leave a message or send a notification to the WeChat Official Account backend, specifying the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.